# Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

> **NCT01844505** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 945 (actual)

## Conditions studied

- Unresectable or Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Placebo for Nivolumab
- **BIOLOGICAL:** Placebo for Ipilimumab

## Key facts

- **NCT ID:** NCT01844505
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-11
- **Primary completion:** 2016-08-01
- **Final completion:** 2024-04-19
- **Target enrollment:** 945 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844505, "Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01844505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*